Theriva Biologics Sells Syn-004 Portfolio to Biossil Labs
Theriva Biologics announced the sale of Syn-004 (ribaxamase) and its related antibiotic-degrading enzyme portfolio to Biossil Labs Inc.
Related stories
Hull Street Energy Completes Acquisition of FirstLight's U.S. Generation Fleet
M impact | MNA | Nov 02, 2026, 04:00 PM UTC
Andersen Group Completes Acquisitions in the Netherlands and of Clareo Partners and Endeavor Management
Andersen Group says it has completed the acquisitions of Andersen in the Netherlands, Clareo Partners and Endeavor Management.
M impact | MNA | Nov 02, 2026, 03:58 PM UTC
Andersen Group Closes Acquisitions of Andersen Netherlands, Clareo Partners and Endeavor Management
M impact | MNA | Nov 02, 2026, 03:58 PM UTC
Andersen Group Closes Three Acquisitions, Completes 16 of 19 Signed in 2026
The three acquisitions are Andersen in the Netherlands, Clareo Partners and Endeavor Management. The 19 deals signed in 2026 represent approximately $190 million in combined annual
M impact | MNA | Nov 02, 2026, 03:58 PM UTC
Andersen Group Closes Three Strategic Acquisitions
M impact | MNA | Nov 02, 2026, 03:58 PM UTC
Bloomin’ Brands proposes buying assets of bankrupt franchisee
Bloomin’ Brands has proposed acquiring assets of a bankrupt franchisee.
L impact | MNA | Nov 02, 2026, 03:57 PM UTC